A review of antiviral therapies in the treatment of cytomegalovirus |
| |
Authors: | Adrienne M. Hinkle,Jo Ann Lee,Katherine A. Bell,& ,Sylvia Hsu |
| |
Affiliation: | Department of Dermatology, Baylor College of Medicine, Houston, Texas |
| |
Abstract: | ABSTRACT: Cytomegalovirus (CMV) is a member of the herpesvirus family that is very prevalent world wide based on serologic testing. In immunocompromised persons CMV produces high rates of morbidity and mortality. Congenital CMV is the leading infectious cause of fetal abnormalities in the United States. Infection of human immunodeficiency virus (HIV) seropositive persons or transplant patients with CMV can produce retinitis, encephalitis, pneumonitis, hepatitis, gastrointestinal ulcerations, and cutaneous lesions. Three intravenous therapies are available for CMV infections: ganciclovir; foscarnet and cidofovir. Most recently a fourth antiviral agent was approved for intravitreal injection. This drug, fomivirsen, is the first antisense oligonucleotide available for therapeutic use. A number of other antiviral drugs and vaccines are currently under study. |
| |
Keywords: | cidofovir cytomegalovirus fomivirsen foscarnet ganciclovir |
|
|